Posted by Michael Wonder on 27 Aug 2025
Leo Pharma announces Health Canada approval of Anzupgo for treatment of moderate to severe chronic hand eczema
26 August 2025 - Approval was based on results from the DELTA 1 and 2 trials, which evaluated the safety and efficacy of Anzupgo compared to cream vehicle.
Leo Pharma Canada is pleased to announce that Health Canada has approved Anzupgo (delgocitinib cream 20 mg/g) for the treatment of adult (aged ≥18 years) patients with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or are not advisable.
